Natunola Releases Q3 2009 Results

WINCHESTER, ON, Nov. 18 /CNW Telbec/ - Natunola Health Biosciences Inc. (TSX-V:NHI) ("Natunola") reports that the revenue for the quarter ended on September 30, 2009 was $311,656 as compared to $475,058 for the comparative period for 2008, which represented a decrease of $163,402 or 34.4%. The decrease in revenue is due to the decrease in sales in flax products during the quarter. As a result, the Company had a net loss of $154,678 or -$0.01 per share for the quarter ended on September 30, 2009 as compared to a net loss of $97,670 or $0.00 per share for the comparative period for 2008.

The sales of the Company's flax products decreased by $191,348 or 48.9% for the quarter ended September 30, 2009 versus the comparative period for 2008. The decrease is due to fewer shipment of the flax product to a specific customer. The sales of the Company's cosmetic and personal care products increased by $39,196 or 54.1% for the quarter ended September 30, 2009 versus the comparative period for 2008.

General expenses declined by $99,531 or 10.6% for the nine months ended September 30, 2009 versus the comparative period for the nine months ended September 30, 2008 . The decrease is due to lower expenses in both sales and marketing and the research and development cost. Included as part of general expenses is a year-to-date foreign exchange loss of $29,968 . For the comparative period last year, there was a foreign exchange gain of $41,589 , as net difference of $71,557 .

Gross margins decreased slightly by 4.4% for the nine months ended September 30, 2009 versus comparative period for 2008. The decrease in gross margins is due to the lower sales.

The sales of the Company's flax products decreased by $630,769 or 44.9% for the nine months ended September 30, 2009 versus the comparative period for 2008. The sales of the Company's cosmetic and personal care products increased slightly by $4,400 or 1.8% for the nine months ended September 30, 2009 versus the comparative period for 2008. As a result of these, the Company recorded a net loss of $303,513 or -$0.02 per share for the nine months ended September 30, 2009 as compared to a net loss of $2,381 or $0.00 per share for the comparative period for 2008.

Some of the statements contained in the release are forward-looking statements, such as estimates and statements that describe the Company's future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. Actual results in each case could differ materially from those currently anticipated in such statements.

    
    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this press release.
    

%SEDAR: 00009761E

For further information: Dr. Nam Fong Han, President & CEO, Natunola Health Biosciences Inc., 661, St Lawrence Street, Winchester, Ontario, K0C 2K0, Tel [phone]